Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on April 8, 2025
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
GlobeNewswire
·
April 8, 2025
FRIENDSWOOD, Texas, April 08, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, is supporting key educational programs and initiatives throughout the month of …
Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease
GlobeNewswire
·
April 8, 2025
VANCOUVER, British Columbia, April 08, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce …
Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA
GlobeNewswire
·
April 8, 2025
FDA action allows for unrestricted distribution of EGRIFTA SV®, removing uncertainty with respect to all manufactured batches PAS approval follows recent FDA approval of new formulation, EGRIFTA WR™ MONTREAL, April 08, 2025 (GLOBE NEWSWIRE) -- …
Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial
GlobeNewswire
·
April 8, 2025
After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12 Deepest and most compelling sustained responses observed in …
Tilray Brands Reports Q3 Fiscal 2025 Financial Results
GlobeNewswire
·
April 8, 2025
Tilray Confirms No Current Impact of Tariffs Generated Net Revenue of $186 Million in the Third Quarter, $193 Million in Constant Currency; Strategic Initiatives and SKU Rationalization Impacted Revenue by $13 Million Tilray Beverage Expands U.S. …
Theratechnologies reçoit l’approbation de la FDA pour le supplément d’approbation préalable [PAS] relatif à sa demande d’un supplément à la licence de produit biologique (sBLA) pour EGRIFTA SV(MD)
GlobeNewswire
·
April 8, 2025
L’approbation de la FDA permet une distribution sans restriction d’EGRIFTA SVMD, levant ainsi l'incertitude concernant tous les lots fabriqués L’approbation du PAS fait suite à l’approbation récente de la nouvelle formulation, EGRIFTA WRMC MONTRÉAL, 08 avr …
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
GlobeNewswire
·
April 8, 2025
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the …
Routine medical appointments and cancer screenings head in the wrong direction
GlobeNewswire
·
April 8, 2025
ALEXANDRIA, Va., April 08, 2025 (GLOBE NEWSWIRE) -- When was the last time you saw your doctor? There’s been a change in how often U.S. adults are going to routine medical appointments and cancer screenings, and according to the Prevent Cancer Foundation’s …
Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
GlobeNewswire
·
April 8, 2025
Vancouver, Canada, April 08, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to …
Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus
GlobeNewswire
·
April 8, 2025
PITTSBURGH, April 08, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced the …
Phonak Audéo Sphere Infinio wins Gold Edison Award for innovation in consumer solutions
GlobeNewswire
·
April 8, 2025
STÄFA, Switzerland, April 08, 2025 (GLOBE NEWSWIRE) -- Phonak, a global leader in innovative hearing solutions, is proud to announce that the Phonak Audéo Sphere Infinio has been awarded the prestigious Gold Edison Award in the category of Consumer …
Nyxoah Provides Update on FDA Approvable Letter for Genio System
GlobeNewswire
·
April 8, 2025
Nyxoah Provides Update on FDA Approvable Letter for Genio System Expects to meet final FDA requirements for full PMA approval in the second quarter Mont-Saint-Guibert, Belgium – April 8, 2025, 07:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: …
BioVersys to Present BV100 Phase 2 Data at 35th ESCMID Global 2025
GlobeNewswire
·
April 8, 2025
BASEL, Switzerland, April 08, 2025 (GLOBE NEWSWIRE) -- Oral presentation on April 13, 2025, highlighting positive BV100 Phase 2 VABP trial read-out with excellent efficacy and safety data Complementary poster presentations featuring clinical …
Nyxoah Présente une Mise à Jour Concernant la Lettre d'Approuvabilité de la FDA pour le Système Genio
GlobeNewswire
·
April 8, 2025
Nyxoah Présente une Mise à Jour Concernant la Lettre d'Approuvabilité de la FDA pour le Système Genio Prévoit de satisfaire aux exigences finales de la FDA pour obtenir l'approbation PMA complète au cours du deuxième trimestre Mont-Saint-Guibert, Belgique …
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
GlobeNewswire
·
April 8, 2025
ADAPT-NXT data demonstrate consistent, sustained disease control across dosing schedules, further supporting individualized VYVGART dosing for gMG patients ADHERE+ oral presentation features long-term CIDP data demonstrating VYVGART Hytrulo’s durable …